European Primary Care Cardiovascular Society

EPCCS Practical Guidance on Heart Failure Diagnosis and Management in Primary Care

Sep. 28, 2016 - news

Based on the Heart Failure session and discussion during the 8th EPCCS Annual Meeting in Prague, this guidance document was written to help physicians diagnose and manage heart failure in their primary care practice.

Increased mortality risk if initiation of HF therapy is delayed

Nov. 27, 2017 - Zaman S et al., Eur J Heart Fail 2017

Deferral of therapy with ACE inhibitors, beta-blockers, and aldosterone antagonists for 1 year carries an absolute mortality risk of around 1% per month, which is higher than the mortality risk due to therapy mentioned in patient information leaflets.

Decline in sudden death in heart failure over last two decades

July 11, 2017 - Shen L, et al, NEJM 2017

A meta-analysis showed that the rate of sudden death in HFrEF patients has fallen over the past two decades, suggesting a cumulative benefit of evidence-based medications on sudden death.

EPCCS Heart Failure Guidance published as Clinical Intelligence in Br J Gen Prac

July 1, 2017 - news

A brief version of our EPCCS Practical Guidance on Heart Failure Diagnosis and Management in Primary Care has now been published as Clinical Intelligence paper in the British Journal of General Practice.

Reaching lower than recommended dose ACEi/ARBs or beta-blockers associates with lower survival chance

June 28, 2017 - Ouwerkerk W, et al, Eur Heart J, 2017

In the BIOSTAT-CHF study, reaching less than 50% of the ESC guideline recommended dose of ACE-inhibitor/ARB or beta-blocker doses was associated with worse survival in HF patients. 

Guideline adherence physician improves heart failure outcomes

May 16, 2017 - Komajda M, Eur J Heart Fail 2017

Good adherence to treatment guidelines, in particular prescription of appropriate classes and doses of medications for heart failure, is associated with improved clinical outcomes. 

Significance and recommendations AF-screening

May 10, 2017 - Freedman B, et al, Circulation, 2017

Expert members of AF-SCREEN propose systematic or opportunistic screening approaches for AF based on known published data, to reduce the number of strokes and death. 

Risk of worsening HF accurately identified with multisensory telemonitoring device

May 1, 2017 - news

ESC HF 2017 Based on heart sounds, respiration rate, and volume, thoracic impedance, night heart rate, and daily activity HeartLogic predicts the risk of an HF event independent of baseline variables.

HF patients in sinus rhythm, but not with AF, benefit from reducing heart rate

May 1, 2017 - news

ESC HF 2017 Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality.

New HF category with midrange EF resembles HFrEF, albeit with better outcomes

May 3, 2017 - news

ESC HF 2017 Analysis of CHARM data revealed that outcomes improve with increasing EF up to ~50%, and that candesartan is effective in HFrEF and HFmrEF, but not in HFpEF.

HFpEF patients do not benefit from heart rate reduction

May 3, 2017 - news

ESC HF 2017 In EDIFY, treatment with ivabradine for 8 months reduced heart rate, but did not improve E/e’, exercise capacity or NT-proBNP levels in patients with HFpEF.

Prevention of acute decompensated HF by intensive BP-lowering

Apr. 24, 2017 - Upadhya B, et al, Circ Heart Fail.

In the SPRINT trial, targeting an SBP of <120 mmHg, as compared with <140 mmHg, significantly reduced the risk of developing ADHF by 36% in all predetermined subgroups.